



GENESTRA
BRANDS®

HMF™ Multi Strain (shelf-stable)



16-strain probiotic combination

- Provides 15 billion CFU per capsule from a combination of 16 strains
- Supports gastrointestinal health, abdominal comfort and a healthy microflora‡
- Balances microflora composition†
- No refrigeration necessary
- Potency guaranteed through expiration

HMF™ Multi Strain offers a comprehensive combination of 16 probiotic strains that promote a healthy gut microflora. Each shelf-stable capsule provides a variety of strains to promote colonization in both the small and large intestines. HN019, a probiotic strain included in this formula, was shown in a placebo-controlled trial to promote a healthy gut microflora. It significantly increased *Bifidobacteria* and *Lactobacilli* counts, while reducing the population of *Enterobacteria* (a genus that includes many pathogenic bacteria). Similarly, Genestra's HMF™ probiotic consortium, *Lactobacillus acidophilus* (CUL-60 and CUL-21), *Bifidobacterium bifidum* (CUL-20) and *Bifidobacterium animalis* subsp. *lactis* (CUL-34), contained in HMF™ Multi Strain, has been demonstrated in clinical trials to support abdominal comfort and promote a healthy microflora balance in the gastrointestinal tract. This convenient shelf-stable format has potency guaranteed through expiration and may improve patient compliance.‡

Supplement Facts

Serving Size 1 Capsule
Servings per Container 50

	Amount Per Serving	% DV
Probiotic Consortium	15 billion CFU	*
<i>Lactobacillus acidophilus</i> (CUL-60 & CUL-21)		
<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> (CUL-34) & <i>Bifidobacterium bifidum</i> (CUL-20)		
<i>Lactobacillus salivarius</i> (CUL-61)		
<i>Lactobacillus fermentum</i> (CUL-67)		
<i>Lactobacillus gasseri</i> (CUL-09)		
<i>Lactobacillus acidophilus</i> (NCFM®)		
<i>Lactobacillus casei</i> (CUL-06)		
<i>Lactobacillus paracasei</i> (CUL-08)		
<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> (CUL-62)		
<i>Bifidobacterium breve</i> (CUL-74)		
<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> (HN019)		
<i>Lactobacillus plantarum</i> (CUL-66)		
<i>Streptococcus salivarius</i> subsp. <i>thermophilus</i> (CUL-68)		
<i>Lactobacillus rhamnosus</i> (HN001)		

* Daily Value (DV) not established

Other Ingredients: Microcrystalline cellulose, hypromellose, sunflower lecithin, silica
NCFM® is used with permission under licence.

Recommended Dose

Adults, Adolescents and Children (6 years and older): Take 1 capsule daily or as recommended by your health professional.

Size
50 Vegetarian Capsules

Product Code
10662-50U



Tried, tested and true.

GenestraBrands.com | 1.888.737.6925

HMF™ Multi Strain (shelf-stable)

Scientific Rationale:

The human intestinal tract contains more than 400 bacterial species.¹ This microflora composition can be altered by a number of factors, including diet, occasional stress, certain medications, aging and travel.¹ When the microflora balance is affected in the intestines, common gastrointestinal complaints can occur, including mild bloating and gas.^{2†}

Probiotics are defined by the World Health Organization as “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.³ Probiotics have been found to support gastrointestinal health and contribute to a healthy microflora composition.¹ Studies have shown that they mediate microbial colonization and support the growth of beneficial bacteria in the intestines.¹ Probiotics accomplish this by mediating intestinal pH and strengthening the epithelial barrier.⁴ They mediate the integrity of tight junctions and increase mucin release, which in turn regulates permeability and reduces microbial adherence to cells.^{4,5†}

HMF™ Multi Strain is formulated using probiotic strains that have been used in a wide body of clinical research, including HNO19, NCFM®, and Genestra Brands® HMF™ proprietary *Lactobacillus* and *Bifidobacterium* probiotic consortium.⁶⁻¹² Studies demonstrate that these strains effectively contribute to a healthy gut flora and support gastrointestinal health.^{6-12†}

Microflora Composition

In one randomized, double-blind, placebo-controlled trial, supplementation with HNO19 significantly contributed to a favorable gut flora in aging adults. Elderly participants (over 60 years of age) consumed either a placebo or one of three probiotic supplements daily for four weeks [low (6.5x10⁷ CFU), medium (1.0x10⁹ CFU) or high (5.0x10⁹ CFU)]. Probiotic supplementation significantly increased the mean number of fecal *Bifidobacteria* when compared to baseline levels. As the levels of *Bifidobacteria* naturally decrease with age, supplementation with HNO19 may represent an easy way to promote its proliferation in the intestines.^{9†}

In addition, HNO19 intake significantly increased *Lactobacilli* and *Enterococci* counts in the high and medium groups after four weeks. As *Bifidobacteria* produce acetate and lactate, they may also help to support the growth of *Lactobacilli*. This further demonstrates that daily supplementation with HNO19 can contribute to a healthy gut flora composition in older adults.^{9†}

The HMF™ Probiotic consortium was found to modulate the intestinal microflora composition in a double-blind, placebo-controlled trial. Participants were divided into two groups, receiving either a probiotic

or placebo supplement for 21 days. Fecal samples were collected at baseline (day one) and on days 7 and 35 to determine the average bacterial composition. Each probiotic capsule was taken once daily and contained 2.5x10¹⁰ CFU from a combination of two strains of *Lactobacillus acidophilus* (CUL-60 and CUL-21), *Bifidobacterium animalis* subsp. *lactis* (CUL-34), and *Bifidobacterium bifidum* (CUL-20). HMF probiotic supplementation helped to support the growth of beneficial strains and maintain a healthy microflora balance in adults.^{6†}

Intestinal Transit Time

In a placebo-controlled trial, daily supplementation with HNO19 for two weeks significantly improved whole gut transit time (WGTT) and gastrointestinal comfort and function scores.¹⁰ One hundred adults were randomized to one of three groups, consuming placebo, low- (1.8 billion CFU of HNO19) or high-dose probiotic (17.2 billion CFU of HNO19) capsules daily for two weeks.¹⁰ WGTT was determined using abdominal X-ray scans at baseline and after two weeks of supplementation.¹⁰ Gastrointestinal comfort and function scores were also analyzed between baseline and study completion.¹⁰ Supplementation with HNO19 was dose-dependently associated with a significant improvement in WGTT (25% and 33% decrease for the low- and high-dose groups, respectively).¹⁰ Probiotic supplementation also significantly improved both upper (abdominal comfort, gurgling) and lower (occasional constipation, bowel movement regularity and flatulence) gastrointestinal comfort and function scores.¹⁰ Similarly, a randomized, double-blind, placebo-controlled study found that combined supplementation with HNO19 and *Lactobacillus acidophilus* NCFM® for two weeks significantly reduced transit time compared to the control group.^{11†}

In an eight-week long, double-blind, randomized, placebo-controlled study involving 52 adults, supplementation with a combination of four HMF™ probiotic strains significantly reduced mild intestinal discomfort.¹² Participants were randomized to either the placebo or probiotic capsule group (25 billion CFU from CUL-60, CUL-21, CUL-34 and CUL-20) and consumed one capsule daily for eight weeks.¹² Participants scored their intestinal discomfort (including bloating, satisfaction with bowel habits and quality of life) at baseline and every two weeks during the supplementation period.¹² In comparison with baseline values, probiotic supplementation significantly improved intestinal discomfort scores, including a 22% decrease in days with intestinal discomfort, 32% improvement in satisfaction with bowel habits and 30% improvement in quality of life scores.¹² These improvements were also significantly greater when compared to placebo values.^{12†}

REFERENCES

1. Nagpal R, Yadav H, Kumar M, Jain S. Probiotics and Prebiotics in Food, Nutrition and Health. Boca Raton, FL: CRC Press, 2013. pp.1-24.
2. Fink RN, Lembo AJ. Curr Treat Options Gastro. 2001 Jul;4(4):333-37.
3. Food and Agriculture Organization and World Health Organization Expert Consultation. Córdoba, Argentina: Food and Agriculture Organization of the United Nations and World Health Organization; 2001.
4. Bermudez-Brito M, Plaza-Diaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Ann Nutr Metab. 2012;61(2):160-74.
5. Saulnier N, Zocco MA, Di Caro S, Gasbarrini G, Gasbarrini A. Genes Nutr. 2006 Jun;1(2):107-15.
6. Madden JA, Plummer SF, Tang J, Garaiova I, Plummer NT, Herbison M, et al. Int Immunopharmacol. 2005 Jun;5(6):1091-7.
7. Plummer SF, Garaiova I, Sarvotham T, Cottrell SL, Le Scouiller S, Weaver MA, et al. Int J Antimicrob Agents. 2005 Jul;26(1):69-74.
8. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. World J Gastroenterol. 2013 Sep;19(36):5973-80.
9. Ahmed M, Prasad J, Gill H, Stevenson L, Gopal P. J Nutr Health Aging. 2007 Jan-Feb;11(1):26-31.
10. Waller AP, Gopal PK, Leyer GJ, Ouwehand AC, Reifer C, Stewart ME, Miller LE. Scand J Gastroenterol. 2011 Sept;46(9):1057-64.
11. Magro DO, de Oliveira LM, Bernasconi I, Ruela Mde S, Credidio L, Barcelos IK, et al. Nutr J. 2014 Jul;13:75.
12. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, et al. Aliment Pharmacol Ther. 2009 Jan;29(1):97-103.

Tried, tested and true.
GenestraBrands.com | 1.888.737.6925



GENESTRA
BRANDS®